Drug recall · April 10, 2013
Tizanidine Tablets USP recall
Why: Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Tizanidine Tablets USP, 4 mg, 150-count tablets per bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachepally - 500 090 India; NDC 55111-180-15.
- Lots / codes
Lot #: C208625, C208984, C209113, C209369, Exp 09/15; and C209680, Exp 10/15.
- Quantity
- 117,546 bottles
- Company
- Dr. Reddy'S Laboratories, Bridgewater, NJ
- Distribution
- Nationwide and Puerto Rico.
- Initiated
- March 19, 2013 · Voluntary: Firm initiated
- Classified
- April 1, 2013
- Reported
- April 10, 2013
- Ended
- February 6, 2014
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tizanidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.